GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » PB Ratio

LXRX (Lexicon Pharmaceuticals) PB Ratio : 1.64 (As of Dec. 16, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Lexicon Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-16), Lexicon Pharmaceuticals's share price is $0.8103. Lexicon Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 was $0.49. Hence, Lexicon Pharmaceuticals's PB Ratio of today is 1.64.

The historical rank and industry rank for Lexicon Pharmaceuticals's PB Ratio or its related term are showing as below:

LXRX' s PB Ratio Range Over the Past 10 Years
Min: 1.35   Med: 4.12   Max: 54.76
Current: 1.64

During the past 13 years, Lexicon Pharmaceuticals's highest PB Ratio was 54.76. The lowest was 1.35. And the median was 4.12.

LXRX's PB Ratio is ranked better than
66.43% of 1281 companies
in the Biotechnology industry
Industry Median: 2.48 vs LXRX: 1.64

During the past 12 months, Lexicon Pharmaceuticals's average Book Value Per Share Growth Rate was -13.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -29.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lexicon Pharmaceuticals was 19.50% per year. The lowest was -38.20% per year. And the median was -17.40% per year.

Back to Basics: PB Ratio


Lexicon Pharmaceuticals PB Ratio Historical Data

The historical data trend for Lexicon Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals PB Ratio Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.77 3.10 5.16 3.08 4.03

Lexicon Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.91 4.03 2.05 2.53 3.18

Competitive Comparison of Lexicon Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Lexicon Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's PB Ratio falls into.



Lexicon Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Lexicon Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=0.8103/0.494
=1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Lexicon Pharmaceuticals  (NAS:LXRX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Lexicon Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Executives
Philippe Amouyal director C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats director, officer: President and CEO 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner officer: SVP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade officer: EVP, Gen. Counsel 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott officer: VP, Human Resources 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a. director, 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc director, 10 percent owner 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth officer: VP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub officer: SVP, Regulatory & QA 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander officer: VP, Finance and Accounting 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz officer: SVP, Chief Medical Officer 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer officer: VP, Finance & Acctg 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381

Lexicon Pharmaceuticals Headlines

From GuruFocus